Quoin Pharmaceuticals

Quoin Pharmaceuticals, Inc. was founded in 2018 as an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. We are committed to addressing unmet medical needs for patients and their families, communities, and care teams. Quoin’s innovative pipeline includes three products with the collective potential to target multiple rare and orphan conditions, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others. The company plans to establish sales infrastructure in the United States and Europe to commercialize its products while seeking strategic licensing partnerships in all other regions. We are dedicated to finding unique solutions for rare and orphan conditions and will continue to expand our product pipeline to meet the unmet needs of underserved patient populations.